News Release Details
| Three Months Ended | ||||||||||
| (In millions, except per share amounts) |
|
|
|
|
|
|||||
| Continuing Operations |
2021 |
|
2020 |
|
Chg |
|||||
| Net revenue |
$ |
1,161.6 |
$ |
1,122.4 |
|
3.5 |
% |
|||
| Net income (loss) |
$ |
28.5 |
$ |
(1.1 |
) |
NM |
|
|||
| Segment profit [1] |
$ |
75.1 |
$ |
41.6 |
|
80.6 |
% |
|||
| Adjusted net income [1] |
$ |
35.5 |
$ |
6.0 |
|
490.1 |
% |
|||
| Earnings (loss) per share |
$ |
1.07 |
$ |
(0.04 |
) |
NM |
|
|||
| Adjusted earnings per share [1] |
$ |
1.33 |
$ |
0.25 |
|
432.0 |
% |
|||
| [1] Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. | ||||||||||
| NM = "not meaningful" | ||||||||||
First Quarter 2021 Highlights and Other Recent Developments:
- Net revenue increased 3.5% percent over the first quarter of 2020 to
$1.16 billion . - Net income increased by
$29.6 million over the first quarter of 2020 to$28.5 million . - Segment profit increased 80.6% percent over the first quarter of 2020 to
$75.1 million . - Adjusted net income and adjusted earnings per share were
$35.5 million and$1.33 as compared to the prior year period of$6.0 million and$0.25 , respectively. - On
March 18, 2021 , Magellan announced that it had been selected to, once again, serve as a contractor for the Military and Family Life Counseling program, which provides counseling for adults and children in the military community. - On
March 31, 2021 , Magellan’s shareholders adopted the plan of merger with Centene Corporation (“Centene”). The Merger Agreement provides for the acquisition by Centene at a price of$95 per share of Magellan common stock in cash. The Company continues to expect the transaction to close during the second half of 2021.
“I am pleased with our first quarter 2021 results, which reflect the progress of the collective efforts of our associates to transform, innovate and grow our businesses. Our pipeline of potential new business opportunities continues to build as customers recognize the growing value of our solutions in the market,” said
“We are also making significant progress in our integration planning efforts with Centene, and we remain enthusiastic about the transaction,” continued Fasola. “We look forward to a new chapter of growth and innovation as a payer services business operating independently under Centene’s
Net Revenue
Net revenue from continuing operations was
Segment Profit
Segment profit from continuing operations was
- Healthcare segment profit was
$41.3 million , representing an increase of$5.7 million from 2020. This year-over-year increase was primarily driven by net business growth partially off-set by an increase in corporate allocations.
- Pharmacy Management segment profit was
$43.7 million , representing an increase of$22.8 million from 2020. This year-over-year increase was primarily driven by revenue growth across specialty, government and commercial PBM, improved gross margin, proceeds from the settlement of a legal matter, and the exit from Medicare Part D. These gains were partially off-set by an increase in corporate allocations and start-up costs associated with a new contract implementation.
- Corporate segment costs inclusive of eliminations, but excluding stock compensation expense, totaled
$9.9 million , as compared to$14.9 million in 2020. This decrease was primarily driven by the reduction of stranded corporate overhead expenses associated with discontinued operations in the prior year quarter.
Other Items
The Company recorded a special charge of
The loss from discontinued operations, net of tax, for the first quarter of 2021 was
Cash Flow & Balance Sheet
Cash flow used in operating activities from continuing operations for the three months ended
As of
Earnings Conference Call
Due to the pending transaction with Centene, the Company is not hosting a conference call in conjunction with its first quarter 2021 earnings release and does not expect to do so in future quarters. Please direct any questions regarding this earnings release to Magellan’s Investor Relations or Media contacts.
Basis of Presentation
In addition to results determined under Generally Accepted Accounting Principles (GAAP), Magellan provides certain non-GAAP financial measures that management believes are useful in assessing the Company’s performance. Following is a description of these important non-GAAP measures.
Segment profit is equal to net revenue less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries and the settlement of a legal matter, but excludes segment profit or loss from non-controlling interests held by other parties, stock compensation expense, special charges or benefits, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions to exclude non‑cash stock compensation expense resulting from restricted stock purchases by sellers, changes in the fair value of contingent consideration, amortization of identified acquisition intangibles, as well as impairment of identified acquisition intangibles, special charges, and any impact related to the sale of MCC.
Included in the tables issued with this press release are the reconciliations from GAAP measures to the corresponding non-GAAP measures.
MCC Business Reflected as Discontinued Operations
Due to the sale of the MCC Business to Molina, the consolidated financial statements for all periods presented reflect the MCC Business as discontinued operations.
About
Forward-Looking Statements
This press release include statements which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events that may not prove to be accurate. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Important proposed merger-related and other risk factors that may cause such differences include: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed merger; (ii) the transaction closing conditions may not be satisfied in a timely manner or at all, including due to the failure to obtain regulatory approvals; (iii) the announcement and pendency of the proposed merger may disrupt the Company’s business operations (including the threatened or actual loss of employees, customers or suppliers); and (iv) the Company could experience financial or other setbacks if the transaction encounters unanticipated problems. Other important factors that could cause actual results to differ materially from those expressed or implied include the effectiveness of business continuity plans during, and the risks associated with, the COVID-19 pandemic; termination or non-renewal of customer contracts; changes in rates paid to and/or by the Company by customers and/or providers; our ability to develop and maintain satisfactory relationships with providers; higher utilization of healthcare services by the Company’s members; risks and uncertainties associated with the pharmacy benefits management industry; costs to maintain or upgrade our information technology and other business systems and the effectiveness and security of such systems; cyberattacks, other privacy/data security incidents, and/or our failure to comply with related regulations; delays, higher costs or inability to obtain and/or implement new business or other Company initiatives; the impact of changes in the contracting model for Medicaid contracts; impairment of our goodwill and intangible assets; the impact of new or amended laws or regulations; costs and other liabilities associated with litigation, government investigations, audits or reviews; competition; operational issues; healthcare reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended
| CONSOLIDATED BALANCE SHEETS | ||||||||||
| (In thousands) | ||||||||||
|
|
|
|
|
|||||||
|
|
|
|
(unaudited) |
|||||||
| ASSETS | ||||||||||
| Current Assets: | ||||||||||
| Cash and cash equivalents |
$ |
1,144,450 |
|
$ |
456,309 |
|
||||
| Accounts receivable, net |
|
743,502 |
|
|
793,504 |
|
||||
| Short-term investments |
|
140,847 |
|
|
625,600 |
|
||||
| Pharmaceutical inventory |
|
43,334 |
|
|
46,389 |
|
||||
| Other current assets |
|
84,264 |
|
|
101,462 |
|
||||
| Total Current Assets |
|
2,156,397 |
|
|
2,023,264 |
|
||||
| Property and equipment, net |
|
136,739 |
|
|
142,084 |
|
||||
| Long-term investments |
|
2,612 |
|
|
4,830 |
|
||||
| Deferred income taxes |
|
1,842 |
|
|
921 |
|
||||
| Other long-term assets |
|
108,797 |
|
|
119,947 |
|
||||
|
|
873,779 |
|
|
873,830 |
|
|||||
| Other intangible assets, net |
|
79,689 |
|
|
71,631 |
|
||||
| Total Assets |
$ |
3,359,855 |
|
$ |
3,236,507 |
|
||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||
| Current Liabilities: | ||||||||||
| Accounts payable |
$ |
137,380 |
|
$ |
149,760 |
|
||||
| Accrued liabilities |
|
354,906 |
|
|
266,217 |
|
||||
| Medical claims payable |
|
111,851 |
|
|
116,580 |
|
||||
| Other medical liabilities |
|
126,921 |
|
|
123,109 |
|
||||
| Current debt, finance lease and deferred financing obligations |
|
6,521 |
|
|
6,543 |
|
||||
| Total Current Liabilities |
|
737,579 |
|
|
662,209 |
|
||||
| Long-term debt, finance lease and deferred financing obligations |
|
631,855 |
|
|
526,682 |
|
||||
| Deferred income taxes |
|
7,102 |
|
|
13,602 |
|
||||
| Tax contingencies |
|
11,002 |
|
|
11,867 |
|
||||
| Deferred credits and other long-term liabilities |
|
69,283 |
|
|
79,276 |
|
||||
| Total Liabilities |
|
1,456,821 |
|
|
1,293,636 |
|
||||
| Redeemable non-controlling interest |
|
33,062 |
|
|
33,303 |
|
||||
| Stockholders’ Equity: | ||||||||||
| Ordinary common stock |
|
555 |
|
|
558 |
|
||||
| Additional paid-in capital |
|
1,477,219 |
|
|
1,488,975 |
|
||||
| Retained earnings |
|
1,857,130 |
|
|
1,884,957 |
|
||||
| Accumulated other comprehensive loss |
|
(205 |
) |
|
(195 |
) |
||||
| Ordinary common stock in treasury, at cost |
|
(1,464,727 |
) |
|
(1,464,727 |
) |
||||
| Total Stockholders’ Equity |
|
1,869,972 |
|
|
1,909,568 |
|
||||
| Total Liabilities and Stockholders’ Equity |
$ |
3,359,855 |
|
$ |
3,236,507 |
|
||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | ||||||||||
| (Unaudited) | ||||||||||
| (In thousands, except per share amounts) | ||||||||||
|
Three Months Ended |
||||||||||
|
|
||||||||||
|
2020 |
|
|
2021 |
|||||||
| Net revenue: | ||||||||||
| Managed care and other |
$ |
553,168 |
|
$ |
626,076 |
|
||||
| PBM |
|
569,211 |
|
|
535,573 |
|
||||
| Total net revenue |
|
1,122,379 |
|
|
1,161,649 |
|
||||
| Costs and expenses: | ||||||||||
| Cost of care |
|
349,108 |
|
|
379,191 |
|
||||
| Cost of goods sold |
|
533,241 |
|
|
492,370 |
|
||||
| Direct service costs and other operating expenses (1) |
|
204,241 |
|
|
231,021 |
|
||||
| Legal matter settlement |
|
- |
|
|
(9,000 |
) |
||||
| Depreciation and amortization |
|
23,358 |
|
|
21,417 |
|
||||
| Interest expense |
|
8,958 |
|
|
6,426 |
|
||||
| Interest and other income |
|
(1,219 |
) |
|
(341 |
) |
||||
| Special charges |
|
- |
|
|
1,151 |
|
||||
| Total costs and expenses |
|
1,117,687 |
|
|
1,122,235 |
|
||||
| Income from continuing operations before income taxes |
|
4,692 |
|
|
39,414 |
|
||||
| Provision for income taxes |
|
5,762 |
|
|
10,905 |
|
||||
| Net (loss) income from continuing operations |
|
(1,070 |
) |
|
28,509 |
|
||||
| Income (loss) from discontinued operations, net of tax |
|
19,320 |
|
|
(682 |
) |
||||
| Net Income |
$ |
18,250 |
|
$ |
27,827 |
|
||||
| Weighted average number of common shares outstanding — basic |
|
24,728 |
|
|
25,948 |
|
||||
| Weighted average number of common shares outstanding — diluted |
|
24,869 |
|
|
26,553 |
|
||||
| Net (loss) income per common share — basic | ||||||||||
| Continuing operations |
$ |
(0.04 |
) |
$ |
1.10 |
|
||||
| Discontinued operations |
|
0.78 |
|
|
(0.03 |
) |
||||
| Consolidated operations |
$ |
0.74 |
|
$ |
1.07 |
|
||||
| Net (loss) income per common share — diluted | ||||||||||
| Continuing operations |
$ |
(0.04 |
) |
$ |
1.07 |
|
||||
| Discontinued operations |
|
0.78 |
|
|
(0.03 |
) |
||||
| Consolidated operations |
$ |
0.74 |
|
$ |
1.04 |
|
||||
| Net income |
$ |
18,250 |
|
$ |
27,827 |
|
||||
| Other comprehensive income: | ||||||||||
| Unrealized (loss) gain on available-for-sale securities (2) |
|
(201 |
) |
|
10 |
|
||||
| Comprehensive income |
$ |
18,049 |
|
$ |
27,837 |
|
||||
|
(1) |
Includes stock compensation expense of |
||||||
|
(2) |
Net of income tax (benefit) provision of |
||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (Unaudited) | |||||||||
| (In thousands) | |||||||||
|
Three Months Ended |
|||||||||
|
|
|||||||||
|
2020 |
|
|
2021 |
||||||
| Cash flows from operating activities: | |||||||||
| Net income |
$ |
18,250 |
|
$ |
27,827 |
|
|||
| Adjustments to reconcile net income to net cash from operating activities: | |||||||||
| Depreciation and amortization |
|
28,684 |
|
|
21,417 |
|
|||
| Special charges |
|
- |
|
|
1,151 |
|
|||
| Non-cash interest expense |
|
585 |
|
|
355 |
|
|||
| Non-cash stock compensation expense |
|
6,057 |
|
|
7,057 |
|
|||
| Non-cash income tax provision |
|
7,802 |
|
|
7,603 |
|
|||
| Non-cash accretion on investments |
|
325 |
|
|
592 |
|
|||
| Changes in assets and liabilities, net of effects from acquisitions of businesses: | |||||||||
| Accounts receivable, net |
|
(33,291 |
) |
|
(50,013 |
) |
|||
| Pharmaceutical inventory |
|
2,629 |
|
|
(3,055 |
) |
|||
| Other assets |
|
(41,862 |
) |
|
(27,283 |
) |
|||
| Accounts payable and accrued liabilities |
|
52,746 |
|
|
(76,183 |
) |
|||
| Medical claims payable and other medical liabilities |
|
(13,622 |
) |
|
917 |
|
|||
| Tax contingencies |
|
925 |
|
|
680 |
|
|||
| Deferred credits and other long-term liabilities |
|
3,003 |
|
|
9,993 |
|
|||
| Other |
|
(505 |
) |
|
1,067 |
|
|||
| Net cash provided by (used in) operating activities |
|
31,726 |
|
|
(77,875 |
) |
|||
| Net cash provided by operating activities from discontinued operations |
|
35,805 |
|
|
- |
|
|||
| Net cash used in operating activities from continuing operations |
|
(4,079 |
) |
|
(77,875 |
) |
|||
| Cash flows from investing activities: | |||||||||
| Capital expenditures |
|
(15,719 |
) |
|
(19,540 |
) |
|||
| Acquisitions and investments in businesses, net of cash acquired |
|
(369 |
) |
|
(2,372 |
) |
|||
| Purchases of investments |
|
(164,311 |
) |
|
(673,169 |
) |
|||
| Proceeds from maturities and sales of investments |
|
152,394 |
|
|
185,619 |
|
|||
| Net cash used in investing activities |
|
(28,005 |
) |
|
(509,462 |
) |
|||
| Net cash used in investing activities from discontinued operations |
|
(19,154 |
) |
|
- |
|
|||
| Net cash used in investing activities from continuing operations |
|
(8,851 |
) |
|
(509,462 |
) |
|||
| Cash flows from financing activities: | |||||||||
| Proceeds from borrowings on revolving line of credit |
|
80,000 |
|
|
- |
|
|||
| Proceeds from exercise of stock options |
|
10,903 |
|
|
7,467 |
|
|||
| Payments on debt, finance lease and deferred financing obligations |
|
(34,774 |
) |
|
(105,506 |
) |
|||
| Other |
|
(1,136 |
) |
|
(2,765 |
) |
|||
| Net cash provided by (used in) financing activities |
|
54,993 |
|
|
(100,804 |
) |
|||
| Net cash provided by financing activities from discontinued operations |
|
- |
|
|
- |
|
|||
| Net cash provided by (used in) financing activities from continuing operations |
|
54,993 |
|
|
(100,804 |
) |
|||
| Net increase (decrease) in cash and cash equivalents |
|
42,063 |
|
|
(688,141 |
) |
|||
| Cash and cash equivalents at beginning of period |
|
115,752 |
|
|
1,144,450 |
|
|||
| Cash and cash equivalents at end of period |
$ |
157,815 |
|
$ |
456,309 |
|
|||
| CONTINUING OPERATIONS RESULTS BY BUSINESS SEGMENT | ||||||||||
| (Unaudited) | ||||||||||
| (In thousands) | ||||||||||
|
Three Months Ended |
||||||||||
|
|
||||||||||
|
2020 |
|
|
2021 |
|||||||
| Healthcare | ||||||||||
| Managed care and other revenue |
$ |
488,906 |
|
$ |
533,010 |
|
||||
| Cost of care |
|
(349,108 |
) |
|
(379,191 |
) |
||||
| Direct service costs and other |
|
(105,936 |
) |
|
(114,993 |
) |
||||
| Stock compensation expense (1) |
|
1,761 |
|
|
2,519 |
|
||||
| Healthcare segment profit |
|
35,623 |
|
|
41,345 |
|
||||
| Pharmacy Management | ||||||||||
| Managed care and other revenue |
|
64,435 |
|
|
93,227 |
|
||||
| PBM revenue |
|
573,778 |
|
|
538,972 |
|
||||
| Cost of goods sold |
|
(537,574 |
) |
|
(495,593 |
) |
||||
| Direct service costs and other |
|
(81,866 |
) |
|
(104,596 |
) |
||||
| Legal matter settlement |
|
- |
|
|
9,000 |
|
||||
| Stock compensation expense (1) |
|
2,107 |
|
|
2,696 |
|
||||
| Pharmacy Management segment profit |
|
20,880 |
|
|
43,706 |
|
||||
| Corporate and Elimination (2) | ||||||||||
| Managed care and other revenue |
|
(173 |
) |
|
(161 |
) |
||||
| PBM revenue |
|
(4,567 |
) |
|
(3,399 |
) |
||||
| Cost of goods sold |
|
4,333 |
|
|
3,223 |
|
||||
| Direct service costs and other |
|
(16,439 |
) |
|
(11,432 |
) |
||||
| Stock compensation expense (1) |
|
1,929 |
|
|
1,842 |
|
||||
| Corporate and Elimination |
|
(14,917 |
) |
|
(9,927 |
) |
||||
| Consolidated | ||||||||||
| Managed care and other revenue |
|
553,168 |
|
|
626,076 |
|
||||
| PBM revenue |
|
569,211 |
|
|
535,573 |
|
||||
| Cost of care |
|
(349,108 |
) |
|
(379,191 |
) |
||||
| Cost of goods sold |
|
(533,241 |
) |
|
(492,370 |
) |
||||
| Direct service costs and other |
|
(204,241 |
) |
|
(231,021 |
) |
||||
| Legal matter settlement |
|
- |
|
|
9,000 |
|
||||
| Stock compensation expense (1) |
|
5,797 |
|
|
7,057 |
|
||||
| Segment profit from continuing operations |
$ |
41,586 |
|
$ |
75,124 |
|
||||
| Reconciliation of income from continuing operations before income taxes (GAAP) to segment profit (non-GAAP): | ||||||||||
| Income from continuing operations before income taxes |
$ |
4,692 |
|
$ |
39,414 |
|
||||
| Stock compensation expense |
|
5,797 |
|
|
7,057 |
|
||||
| Depreciation and amortization |
|
23,358 |
|
|
21,417 |
|
||||
| Interest expense |
|
8,958 |
|
|
6,426 |
|
||||
| Interest and other income |
|
(1,219 |
) |
|
(341 |
) |
||||
| Special charges |
|
- |
|
|
1,151 |
|
||||
| Segment profit from continuing operations |
$ |
41,586 |
|
$ |
75,124 |
|
||||
| (1) Stock compensation expense, changes in the fair value of contingent consideration recorded in relation to acquisitions and impairment of intangible assets are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of segment profit. | ||||||
| (2) Pharmacy Management provides pharmacy benefits management for certain Healthcare customers, and the Company’s employees covered under its medical plan. As such, revenue, cost of goods sold and direct service costs and other related to these arrangements are eliminated. | ||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES | |||||||||
| (Unaudited) | |||||||||
| (In thousands, except per share amounts) | |||||||||
|
Three Months Ended |
|||||||||
|
|
|||||||||
|
2020 |
|
|
2021 |
||||||
| Net (loss) income from continuing operations |
$ |
(1,070 |
) |
$ |
28,509 |
|
|||
| Adjustments | |||||||||
| Stock compensation expense |
|
- |
|
|
246 |
|
|||
| Amortization of acquired intangibles |
|
9,686 |
|
|
8,059 |
|
|||
| Special charges |
|
- |
|
|
1,151 |
|
|||
| Tax impact |
|
(2,605 |
) |
|
(2,492 |
) |
|||
| Adjusted net income from continuing operations |
$ |
6,011 |
|
$ |
35,473 |
|
|||
| Net (loss) income per common share attributable to Magellan —Diluted |
$ |
(0.04 |
) |
$ |
1.07 |
|
|||
| Adjustments | |||||||||
| Stock compensation expense |
|
- |
|
|
0.01 |
|
|||
| Amortization of acquired intangibles |
|
0.39 |
|
|
0.30 |
|
|||
| Special charges |
|
- |
|
|
0.04 |
|
|||
| Tax impact |
|
(0.10 |
) |
|
(0.09 |
) |
|||
| Adjusted earnings per share |
$ |
0.25 |
|
$ |
1.33 |
|
|||
(MGLN-GEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005084/en/
Media Contact:
Investor Contact:
Source: